WAM
SLXNW

Wolverine Asset Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Wolverine Asset Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,735
Closed -$296 – 1806
2024
Q4 		$296 Sell
8,735
-1,200
-12% -$48 ﹤0.01% 1563
2024
Q3 		$314 Buy
+9,935
New +$575 ﹤0.01% 1584

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wolverine Asset Management's SLXNW Position: Q1 2025 in Review

Wolverine Asset Management sold out of Silexion Therapeutics Warrant (SLXNW) in Q1 2025, closing a stake of 8,735 shares — an estimated $296 sold.

Wolverine Asset Management first reported a position in SLXNW in Q3 2024 and held it in 2 quarters. The position peaked at $314 in Q3 2024. 25 funds tracked by Wall St. Rank hold SLXNW as of Q1 2025.

  • Wolverine Asset Management reported no remaining Silexion Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 8,735 Silexion Therapeutics Warrant shares in Q1 2025, an estimated $296.
  • Wolverine Asset Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 2 quarters.
  • Wolverine Asset Management's Silexion Therapeutics Warrant position peaked at $314 in Q3 2024.
  • 25 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.